Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Targeting MIAT reduces apoptosis of cardiomyocytes after ischemia/reperfusion injury.

Tytuł:
Targeting MIAT reduces apoptosis of cardiomyocytes after ischemia/reperfusion injury.
Autorzy:
Chen L; a Department of Internal medicine intensive care , the central hospital of Linyi , Yishui , Shandong , China.
Zhang D; a Department of Internal medicine intensive care , the central hospital of Linyi , Yishui , Shandong , China.
Yu L; a Department of Internal medicine intensive care , the central hospital of Linyi , Yishui , Shandong , China.
Dong H; b Department of Anesthesia , the affiliated hospital of Qingdao University , Qingdao Shandong , China.
Źródło:
Bioengineered [Bioengineered] 2019 Dec; Vol. 10 (1), pp. 121-132.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
MeSH Terms:
Apoptosis Regulatory Proteins/*genetics
Myocardial Reperfusion Injury/*genetics
Myocardium/*metabolism
Myocytes, Cardiac/*metabolism
RNA, Long Noncoding/*genetics
Transcription Factor RelA/*genetics
Tumor Suppressor Proteins/*genetics
Animals ; Apoptosis/genetics ; Apoptosis Regulatory Proteins/antagonists & inhibitors ; Apoptosis Regulatory Proteins/metabolism ; Caspase 3/genetics ; Caspase 3/metabolism ; Cell Hypoxia ; Cell Line ; Cell Survival ; Gene Expression Regulation ; Humans ; L-Lactate Dehydrogenase/metabolism ; Mice ; Myocardial Reperfusion Injury/metabolism ; Myocardial Reperfusion Injury/pathology ; Myocardial Reperfusion Injury/prevention & control ; Myocardium/pathology ; Myocytes, Cardiac/pathology ; Protein Transport ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; RNA, Long Noncoding/antagonists & inhibitors ; RNA, Long Noncoding/metabolism ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Rats ; Signal Transduction ; Transcription Factor RelA/antagonists & inhibitors ; Transcription Factor RelA/metabolism ; Tumor Suppressor Proteins/antagonists & inhibitors ; Tumor Suppressor Proteins/metabolism ; bcl-2-Associated X Protein/genetics ; bcl-2-Associated X Protein/metabolism
References:
Genes Dev. 1999 Feb 15;13(4):400-11. (PMID: 10049356)
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9136-41. (PMID: 10430908)
Oncogene. 1999 Nov 22;18(49):6853-66. (PMID: 10602461)
Oncogene. 1999 Nov 22;18(49):6910-24. (PMID: 10602466)
Eur J Biochem. 2000 Jun;267(12):3828-35. (PMID: 10849002)
Arch Surg. 2000 Jul;135(7):860-6. (PMID: 10896383)
PLoS Biol. 2004 Sep;2(9):E247. (PMID: 15226823)
Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H52-60. (PMID: 16399862)
J Hum Genet. 2006;51(12):1087-99. (PMID: 17066261)
J Cell Sci. 2007 Aug 1;120(Pt 15):2498-506. (PMID: 17623775)
Eur J Pharmacol. 2008 Apr 14;584(1):175-84. (PMID: 18295200)
Cell Death Differ. 2009 Sep;16(9):1192-202. (PMID: 19444283)
Oncogene. 2008 Dec;27 Suppl 1:S71-83. (PMID: 19641508)
Genes Dev. 2012 Feb 1;26(3):203-34. (PMID: 22302935)
Eur Heart J. 2013 Jun;34(24):1834-45. (PMID: 22307460)
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1002-7. (PMID: 24371310)
Mol Cancer Ther. 2014 May;13(5):1298-308. (PMID: 24563542)
Eur J Immunol. 2014 Jul;44(7):2085-95. (PMID: 24723426)
Bioengineered. 2015;6(1):8-19. (PMID: 25424593)
Circ Res. 2015 Mar 27;116(7):1143-56. (PMID: 25587098)
Mol Ther. 2015 Jun;23(6):1034-1043. (PMID: 25743111)
J Cardiovasc Pharmacol Ther. 2016 May;21(3):296-309. (PMID: 26396139)
Nat Rev Cardiol. 2016 Apr;13(4):193-209. (PMID: 26843289)
Ther Clin Risk Manag. 2016 May 24;12:817-24. (PMID: 27307742)
Bioengineered. 2016 Nov;7(6):411-417. (PMID: 27415469)
J Mol Cell Cardiol. 2017 Feb;103:48-55. (PMID: 28077321)
Sci Rep. 2017 Feb 15;7:42657. (PMID: 28198439)
Cardiovasc Res. 2017 May 1;113(6):564-585. (PMID: 28453734)
Cell Physiol Biochem. 2017;42(3):1153-1164. (PMID: 28668956)
Cell. 2018 Jan 25;172(3):393-407. (PMID: 29373828)
J Biomed Sci. 2018 Mar 13;25(1):23. (PMID: 29534728)
Chem Biol Interact. 2019 Feb 25;300:111-122. (PMID: 30611788)
Contributed Indexing:
Keywords: Hypoxia/reoxygenation; apoptosis; ischaemia-reperfusion; lncRNA myocardial infarction-associated transcript; nuclear factor kappa B; p53 upregulated modulator of apoptosis
Substance Nomenclature:
0 (Apoptosis Regulatory Proteins)
0 (Bax protein, mouse)
0 (Miat long non-coding RNA)
0 (PUMA protein, mouse)
0 (Proto-Oncogene Proteins c-bcl-2)
0 (RNA, Long Noncoding)
0 (RNA, Small Interfering)
0 (Rela protein, mouse)
0 (Transcription Factor RelA)
0 (Tumor Suppressor Proteins)
0 (bcl-2-Associated X Protein)
114100-40-2 (Bcl2 protein, mouse)
EC 1.1.1.27 (L-Lactate Dehydrogenase)
EC 3.4.22.- (Casp3 protein, mouse)
EC 3.4.22.- (Caspase 3)
Entry Date(s):
Date Created: 20190412 Date Completed: 20190828 Latest Revision: 20200430
Update Code:
20240104
PubMed Central ID:
PMC6527071
DOI:
10.1080/21655979.2019.1605812
PMID:
30971184
Czasopismo naukowe
This study aims to investigate the role of targeting lncRNA myocardial infarction-associated transcript (MIAT) in protection against hypoxia/reoxygenation (H/R) injury in H9c2 cells in vitro and myocardial ischemia/reperfusion (I/R) injury in vivo by regulating expression of NF-kB and p53 upregulated modulator of apoptosis (PUMA). H9C2 cells were infected with lentivirus expressing the short-hairpin RNA direct against human MIAT gene (Lv-MIAT shRNA) or lentivirus expressing scrambled control (Lv-NC shRNA) or PUMA siRNA or p65 siRNA or their control siRNA respectively. Then the H9c2 cells were infected with Lv-shRNA to 2 hours of hypoxia (H) and 24 hour of reoxygenation (R). 100 ul of Lv-MIAT shRNA (1 × 10 8 PFU) or Lv-NC shRNA was transfected into mouse hearts, then the hearts were subjected to I/R (1h/72 h). We discovered targeting MIAT remarkably enhanced H9c2 cell viability, decreased H/R-induced cell apoptosis and LDH leakage and significantly decreased I/R-induced myocardial infarct size, reduced myocardial apoptosis and enhanced the heart function. Targeting MIAT downregulated p65 nuclear translocation, NF-κB activity and anti-apoptotic protein cleaved-caspase-3, Bax, and upregulated anti-apoptotic protein Bcl-2 induced by H/R or I/R. Our study suggests that targeting MIAT may protect against H9c2 cardiomyoblasts H/R injury or myocardial I/R injury via inhibition of cell apoptosis, mediated by NF-κB and PUMA signal pathway.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies